1-3 of 3
Paul Severson, PhD
Close
Sort by
Journal Articles

Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML

Benjamin J. Huang, MD, Xinyue Wang, BA, Max Harris, BA, Anica Wandler, PhD, Eugene Hwang, BA, Michael R. Burgess, MD PhD, Qing Li, MD PhD, Paul Severson, PhD, Ben Powell, PhD, Edward A. Kolb, MD, Soheil Meshinchi, MDPhD, Barry S Taylor, PhD, Gideon Bollag, PhD, Kevin M. Shannon, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-142921
Published: 2020
Journal Articles

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Alice S. Mims, MD, Melhem Solh, MD, Uma Borate, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Gail J. Roboz, MD, Ben Powell, PhD, Paul Severson, PhD, Bernice Matusow, Jason Halladay, PhD, Ching Hsu, PhD, Paul Watkins, Chao Zhang, PhD, Jackie M. Walling, PhD MD, Athanasios C. Tsiatis, MD, Amy E. DeZern, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-140138
Published: 2020
Journal Articles

A Mixed Type 1 and Type 2 Kinase Inhibitor That Overrides FLT3 F691 and D835 Resistance Mutations

Jack Lin, PhD, Ying Zhang, PhD, Bernice Matusow, Adam Mumy, Garson Tsang, Jiazhong Zhang, PhD, Hannah Powers, Wayne Spevak, PhD, Paul Severson, PhD, James Tsai, Gideon Bollag, PhD, Chao Zhang, PhD
Journal: Blood
Blood (2016) 128 (22): 1074.
https://doi.org/10.1182/blood.V128.22.1074.1074
Published: 2016